Three experts from CAS, the University of Messina, and the Coriell Institute break down how epigenetics has evolved from a niche research area into a clinical force, with 13 FDA-approved drugs, 2,200+ active trials, and a fast-growing diagnostic toolkit reshaping how we detect and treat cancer.



